

Accepted Manuscript

Survival Outcomes, Prostate-Specific Antigen (PSA) Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-Resistant Prostate Cancer (mCRPC): a Real-World Experience in Hong Kong

Darren M.C. Poon, Kenneth C.W. Wong, T.W. Chan, Kitty Law, Kuen Chan, Eric K.C. Lee, Conrad Lee, Michelle Chan

PII: S1558-7673(18)30397-5

DOI: [10.1016/j.clgc.2018.07.008](https://doi.org/10.1016/j.clgc.2018.07.008)

Reference: CLGC 1087

To appear in: *Clinical Genitourinary Cancer*


Received Date: 16 May 2018

Revised Date: 10 July 2018

Accepted Date: 14 July 2018

Please cite this article as: Poon DMC, Wong KCW, Chan TW, Law K, Chan K, Lee EKC, Lee C, Chan M, on Behalf of the Hong Kong Society of Uro-Oncology (HKUSO), Survival Outcomes, Prostate-Specific Antigen (PSA) Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-Resistant Prostate Cancer (mCRPC): a Real-World Experience in Hong Kong, *Clinical Genitourinary Cancer* (2018), doi: 10.1016/j.clgc.2018.07.008.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Survival Outcomes, Prostate-Specific Antigen (PSA) Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-Resistant Prostate Cancer (mCRPC): a Real-World Experience in Hong Kong

Darren M.C. Poon,^{1,8} Kenneth C.W. Wong^{1,8}, T.W. Chan^{2,8}, Kitty Law^{3,8}, Kuen Chan^{4,8}, Eric K.C. Lee^{5,8}, Conrad Lee^{6,8}, Michelle Chan^{7,8} on Behalf of the Hong Kong Society of Uro-Oncology (HKUSO)

¹Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.

²Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong.

³Department of Oncology, Princess Margaret Hospital, Hong Kong.

⁴Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong.

⁵Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong.

⁶Department of Clinical Oncology, United Christian Hospital, Hong Kong.

⁷Department of Clinical Oncology, Queen Mary Hospital, Hong Kong.

⁸Hong Kong Society of Uro-Oncology (HKSUO), Hong Kong.

Running Title: First and Later Lines of Enzalutamide for mCRPC

Address correspondence to:

Dr. Darren Ming-Chun Poon
Department of Clinical Oncology,
State Key Laboratory in Oncology in South China,
Sir YK Pao Centre for Cancer,
Hong Kong Cancer Institute and Prince of Wales Hospital,
The Chinese University of Hong Kong,
Hong Kong
Email: mc_poon@clo.cuhk.edu.hk

Download English Version:

<https://daneshyari.com/en/article/11010415>

Download Persian Version:

<https://daneshyari.com/article/11010415>

[Daneshyari.com](https://daneshyari.com)